89 related articles for article (PubMed ID: 27418392)
1. Reduced food interaction and enhanced gastrointestinal tolerability of a new system based on risedronate complexed with Eudragit E100: Mechanistic approaches from in vitro and in vivo studies.
Guzman ML; Soria EA; Laino C; Manzo RH; Olivera ME
Eur J Pharm Biopharm; 2016 Oct; 107():263-72. PubMed ID: 27418392
[TBL] [Abstract][Full Text] [Related]
2. Enhanced intestinal permeability and oral bioavailability of enalapril maleate upon complexation with the cationic polymethacrylate Eudragit E100.
Ramírez-Rigo MV; Olivera ME; Rubio M; Manzo RH
Eur J Pharm Sci; 2014 May; 55():1-11. PubMed ID: 24456933
[TBL] [Abstract][Full Text] [Related]
3. Fabrication of novel GMO/Eudragit E100 nanostructures for enhancing oral bioavailability of carvedilol.
Patil SS; Roy K; Choudhary B; Mahadik KR
Drug Dev Ind Pharm; 2016 Aug; 42(8):1300-7. PubMed ID: 26651381
[TBL] [Abstract][Full Text] [Related]
4. Interaction between Bisphosphonates and Mineral Water: Study of Oral Risedronate Absorption in Rats.
Itoh A; Akagi Y; Shimomura H; Aoyama T
Biol Pharm Bull; 2016; 39(3):323-8. PubMed ID: 26934925
[TBL] [Abstract][Full Text] [Related]
5. Role of Molecular Interactions for Synergistic Precipitation Inhibition of Poorly Soluble Drug in Supersaturated Drug-Polymer-Polymer Ternary Solution.
Prasad D; Chauhan H; Atef E
Mol Pharm; 2016 Mar; 13(3):756-65. PubMed ID: 26866895
[TBL] [Abstract][Full Text] [Related]
6. Dissolution enhancement of the anti-HIV drug UC 781 by formulation in a ternary solid dispersion with TPGS 1000 and Eudragit E100.
Goddeeris C; Willems T; Houthoofd K; Martens JA; Van den Mooter G
Eur J Pharm Biopharm; 2008 Nov; 70(3):861-8. PubMed ID: 18691650
[TBL] [Abstract][Full Text] [Related]
7. Clinical trial of risedronate in Japanese volunteers: a study on the effects of timing of dosing on absorption.
Ogura Y; Gonsho A; Cyong JC; Orimo H
J Bone Miner Metab; 2004; 22(2):120-6. PubMed ID: 14999522
[TBL] [Abstract][Full Text] [Related]
8. Preparation of Eudragit E100 microspheres by modified solvent evaporation method.
Singh V; Chaudhary AK
Acta Pol Pharm; 2011; 68(6):975-80. PubMed ID: 22125964
[TBL] [Abstract][Full Text] [Related]
9. Eudragit E100 as a drug carrier: the remarkable affinity of phosphate ester for dimethylamine.
Guzmán ML; Manzo RH; Olivera ME
Mol Pharm; 2012 Sep; 9(9):2424-33. PubMed ID: 22808998
[TBL] [Abstract][Full Text] [Related]
10. Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies.
Ogura Y; Gonsho A; Cyong JC; Orimo H
J Bone Miner Metab; 2004; 22(2):111-9. PubMed ID: 14999521
[TBL] [Abstract][Full Text] [Related]
11. The effect of dosing regimen on the pharmacokinetics of risedronate.
Mitchell DY; Heise MA; Pallone KA; Clay ME; Nesbitt JD; Russell DA; Melson CW
Br J Clin Pharmacol; 1999 Oct; 48(4):536-42. PubMed ID: 10583024
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of interpolyelectrolyte complexes of Eudragit E100 with Eudragit L100.
Moustafine RI; Kabanova TV; Kemenova VA; Van den Mooter G
J Control Release; 2005 Mar; 103(1):191-8. PubMed ID: 15710510
[TBL] [Abstract][Full Text] [Related]
13. Eudragit E100 surface activity and lipid interactions.
Alasino RV; Leonhard V; Bianco ID; Beltramo DM
Colloids Surf B Biointerfaces; 2012 Mar; 91():84-9. PubMed ID: 22093374
[TBL] [Abstract][Full Text] [Related]
14. Interaction and complex formation between catalase and cationic polyelectrolytes: chitosan and Eudragit E100.
Boeris V; Romanini D; Farruggia B; Picó G
Int J Biol Macromol; 2009 Aug; 45(2):103-8. PubMed ID: 19397924
[TBL] [Abstract][Full Text] [Related]
15. Enteric-coated tablet of risedronate sodium in combination with phytic acid, a natural chelating agent, for improved oral bioavailability.
Kim JS; Jang SW; Son M; Kim BM; Kang MJ
Eur J Pharm Sci; 2016 Jan; 82():45-51. PubMed ID: 26594027
[TBL] [Abstract][Full Text] [Related]
16. Interaction of a cationic acrylate polymer with caseins: biphasic effect of Eudragit E100 on the stability of casein micelles.
Ausar SF; Bianco ID; Castagna LF; Alasino RV; Beltramo DM
J Agric Food Chem; 2003 Jul; 51(15):4417-23. PubMed ID: 12848519
[TBL] [Abstract][Full Text] [Related]
17. Risedronate activity in the fetal and neonatal mouse.
Richardson AC; Tinling SP; Chole RA
Otolaryngol Head Neck Surg; 1993 Oct; 109(4):623-33. PubMed ID: 8233497
[TBL] [Abstract][Full Text] [Related]
18. Interaction between a cationic polymethacrylate (Eudragit E100) and anionic drugs.
Quinteros DA; Rigo VR; Kairuz AF; Olivera ME; Manzo RH; Allemandi DA
Eur J Pharm Sci; 2008 Jan; 33(1):72-9. PubMed ID: 18060747
[TBL] [Abstract][Full Text] [Related]
19. Increased physical stability and improved dissolution properties of itraconazole, a class II drug, by solid dispersions that combine fast- and slow-dissolving polymers.
Six K; Verreck G; Peeters J; Brewster M; Van Den Mooter G
J Pharm Sci; 2004 Jan; 93(1):124-31. PubMed ID: 14648642
[TBL] [Abstract][Full Text] [Related]
20. Novel Pullulan-Eudragit® S100 blend microparticles for oral delivery of risedronate: formulation, in vitro evaluation and tableting of blend microparticles.
de Arce Velasquez A; Ferreira LM; Stangarlin MF; da Silva Cde B; Rolim CM; Cruz L
Mater Sci Eng C Mater Biol Appl; 2014 May; 38():212-7. PubMed ID: 24656371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
